Novo Holdings Launches Portfolio Company Booster Therapeutics to Advance New Class of Small Molecule Proteasome Activator Therapeutics
- Booster Therapeutics raises $15 million seed financing led by Apollo Health Ventures and Novo Holdings
- Booster Therapeutics’ proteasome activation approach designed to achieve wider degradation of harmful proteins than current targeted protein degraders
- Harmful protein accumulation implicated in range of complex diseases also linked to proteasome dysfunction
Copenhagen, Denmark – October 10, 2024 – Novo Holdings, a leading global life sciences investor, today announced the launch of Booster Therapeutics (Booster / the Company), a biotechnology company developing a new class of proteasome activator medicines to treat neurodegenerative and other diseases. The launch is accompanied by a $15 million seed financing round led by Apollo Health Ventures and Novo Holdings.
